Design Therapeutics, Inc. (DSGN)

In the past six months, DSGN shares reached a new 52-week high of $8.86 on November 25, 2025. Royal Bank of Canada upgraded Design Therapeutics to "outperform" with a price target of $13.00 on November 20, 2025. Wall Street Zen raised Design Therapeutics to a "hold" rating on November 8, 2025. The company reported quarterly earnings on November 5, 2025, with an EPS of ($0.30), surpassing estimates. Weiss Ratings restated a "sell" rating on October 8, 2025. Design Therapeutics announced plans to initiate patient dosing of DT-818 for DM1 in the first half of 2026 and reported its third-quarter 2025 financial results. The company also announced the start of Friedreich Ataxia patient dosing ex-U.S. in its RESTORE-FA Phase 1/2 trial. An FDA clinical hold was placed on the U.S. IND application for DT-216P2.

As a clinical-stage biopharmaceutical company focused on research and development, there is no information available regarding demand seasonality for Design Therapeutics' products and services.

Design Therapeutics, Inc. (DSGN) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutic drugs for serious genetic diseases using its GeneTAC™ platform. The company's pipeline includes product candidates for Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), Myotonic Dystrophy Type-1 (DM1), and Huntington's Disease. DT-216P2 is its product candidate for FA, DT-168 is for FECD, and DT-818 is planned for patient dosing for DM1 in the first half of 2026.

Design Therapeutics, Inc. is headquartered in Carlsbad, California, United States.

Design Therapeutics is perceived as a pioneering and innovative biotechnology company. Analyst sentiment is cautiously optimistic, with a consensus "Hold" rating. Royal Bank of Canada upgraded the stock to "outperform" in November 2025. However, the company is classified as a "Distressed" stock type with a low Piotroski F-Score, suggesting potential financial distress, despite strong liquidity and minimal leverage.

Design Therapeutics, Inc. has significant institutional ownership, ranging from 56.64% to 60.58%. Major institutional owners include SR One Capital Management, LP, Logos Global Management LP, Point72 Asset Management, L.P., BlackRock, Inc., Frazier Life Sciences Management, L.P., Tang Capital Management LLC, Baker Bros. Advisors LP, Almitas Capital LLC, Vanguard Group Inc, and Driehaus Capital Management LLC. Notable individual owners and officers include Dr. Aseem Z. Ansari, Dr. Heather Berger, Dr. Rodney Lappe, Ms. Deepa Prasad, and Mr. John Schmid. Pratik Shah is the CEO.